Comparing PET-CT Using C-11 Choline and 18F-Fluoromethylcholine in Patients With Metastatic Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed prostate cancer
• At least 4 metastatic lesions identified by conventional imaging with bone scintigraphy
• Treatment-naive disease
• PATIENT CHARACTERISTICS:
• WHO performance status 0-2
• Life expectancy ≥ 12 weeks
• Hemoglobin ≥ 9.0 g/dL
• Platelet count ≥ 100 x 10\^9/L
• Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
• ALT and AST ≤ 2.5 times ULN (≤ 5 times ULN if due to tumor)
• Fertile patients must use two forms of effective contraception 2 weeks prior to, during, and for 6 months after completion of study therapy
• None of the following conditions that would prevent compliance with the study protocol:
• * Diabetes
• * High levels of pain/discomfort
• * Urinary incontinence
• No history of recent significant cardiac arrhythmia
• No concurrent congestive heart failure or prior history of NYHA class III-IV cardiac disease
• No other condition that, in the investigator's opinion, would not make the patient a good candidate for the clinical trial
• PRIOR CONCURRENT THERAPY:
• No prior radiotherapy, hormone therapy, chemotherapy, endocrine therapy, or immunotherapy for the treatment of prostate cancer
• No major thoracic and/or abdominal surgery from which the patient has not yet recovered
• No concurrent anticancer therapy
• No concurrent hormone therapy
• No concurrent participation or planning to participate in another interventional clinical trial
• * Concurrent participation in an observational trial allowed
• No other concurrent investigational drugs